ライフサイエンスコーパス: transthoracic echocardiography

1 Velocity-time integral was measured by transthoracic echocardiography.

2 ively evaluated their proficiency in focused transthoracic echocardiography.

3 res of the valve and ventricular function by transthoracic echocardiography.

4 nsional (2D) and 3D (automated true 3D PISA) transthoracic echocardiography.

5 c valve gradient and ventricular function by transthoracic echocardiography.

6 ty using real-time volume color flow Doppler transthoracic echocardiography.

7 -240 kg) without cardiac disease by standard transthoracic echocardiography.

8 acic echocardiography, and three-dimensional transthoracic echocardiography.

9 s underwent baseline clinical evaluation and transthoracic echocardiography.

10 of evidence showing incremental benefit over transthoracic echocardiography.

11 dural hemodynamic parameters were studied by transthoracic echocardiography.

12 with ICE despite being underrecognized with transthoracic echocardiography.

13 diac ventricular function was evaluated with transthoracic echocardiography.

14 and normal right-sided cardiac morphology by transthoracic echocardiography.

15 The presence of PFO was assessed by transthoracic echocardiography.

16 compared with other imaging modalities, even transthoracic echocardiography.

17 cation and aortic stenosis was determined by transthoracic echocardiography.

18 of nuclear extracts) and cardiac function by transthoracic echocardiography.

19 peratively in only 5 of 41 (12%) patients by transthoracic echocardiography.

20 ut after fluid therapy, assessed by a second transthoracic echocardiography.

21 tening, as revealed by gated cardiac MRI and transthoracic echocardiography.

22 y biplane and volumetric (three-dimensional) transthoracic echocardiography.

23 etermine the prevalence of the problem using transthoracic echocardiography.

24 Cardiac function was assessed by transthoracic echocardiography.

25 d-systolic MAD length was 10.58+/-3.49 mm on transthoracic echocardiography.

26 ed at end systole on pre- and post-operative transthoracic echocardiography.

27 f medical-therapy+/-revascularization, using transthoracic echocardiography.

28 5-year increase in age after patients' first transthoracic echocardiography.

29 ancy and placental pathology data to undergo transthoracic echocardiography.

30 under a deep standardized inspiration using transthoracic echocardiography.

31 em agreed to undergo electrocardiography and transthoracic echocardiography.

32 o intensive care, they were reassessed using transthoracic echocardiography.

33 sclerosis Risk in Communities) who underwent transthoracic echocardiography.

34 speckle tracking was assessed with same-day transthoracic echocardiography.

35 tertile [LAA], respectively) as measured by transthoracic echocardiography.

36 s recently emerged as an ideal complement to transthoracic echocardiography.

37 ed by serial right heart catheterization and transthoracic echocardiography.

38 jects or heart failure patients (assessed by transthoracic echocardiography: 177 +/- 47 g vs 203 +/-

39 us (>16 days) Q-wave MI by ECG who underwent transthoracic echocardiography: 194 with IMR quantitativ

40 osis of endocarditis (14%-28%) compared with transthoracic echocardiography (2%-15%).

41 spicion of endocarditis, have had at least a transthoracic echocardiography, 2 pairs of blood culture

42 G, cardiac troponin (24 of 2719 [0.9%]), and transthoracic echocardiography (24 of 2556 [0.9%]).

43 prospectively performed using 2-dimensional transthoracic echocardiography (2D-TTE) in 282 patients

44 m to evaluate the ability of two-dimensional transthoracic echocardiography (2D-TTE) to determine cau

45 cular MR (CMR) and 2-dimensional (2D) and 3D transthoracic echocardiography (2DTTE and 3DTTE) were pe

46 longer than agitated saline bubble-enhanced transthoracic echocardiography (3.2 min) (p < 0.001).

47 d Task Force Criteria and underwent baseline transthoracic echocardiography, 37 (53%) patients experi

48 clinical assessment, chest radiography, and transthoracic echocardiography, a panel of three cardiol

49 zed test in the Medicare population remained transthoracic echocardiography, accounting for 61.5% of

50 isit 5 examination (2011-2013) and underwent transthoracic echocardiography (age, 75+/-6 years; 61% w

51 Transthoracic echocardiography, alone or in sequence wit

52 , population-based cohort, PFO detected with transthoracic echocardiography and agitated saline was n

53 AS severity was diagnosed by transthoracic echocardiography and ATTR-CA by myocardial

54 ography, hemodynamic data were obtained from transthoracic echocardiography and cardiac catheterizati

55 (1) Multimodality cardiovascular imaging (transthoracic echocardiography and cardiac magnetic reso

56 atients were characterized with conventional transthoracic echocardiography and cardiac magnetic reso

57 In routine practice, transthoracic echocardiography and cinefluoroscopy compr

58 -gradient pattern was determined at baseline transthoracic echocardiography and classified as follows

59 chronic native AR evaluated by 2-dimensional transthoracic echocardiography and CMR examination withi

60 e normal global cardiac function by standard transthoracic echocardiography and CMR measures.

61 , despite normal global systolic function by transthoracic echocardiography and CMR.

62 dentified by agitated saline bubble-enhanced transthoracic echocardiography and confirmed by chest ra

63 Using transthoracic echocardiography and coronary computed tom

64 ch fellow's knowledge with regard to focused transthoracic echocardiography and each fellow's ability

65 n-Meier estimates, the time between baseline transthoracic echocardiography and experiencing MACE was

66 opulmonary hypertension may be screened with transthoracic echocardiography and following up with a r

67 Indexes from transthoracic echocardiography and hemodynamic evaluatio

68 y and the recently developed tri-dimensional transthoracic echocardiography and intracardiac echocard

69 ine-stimulated cardiac function, measured by transthoracic echocardiography and left ventricular micr

70 Transthoracic echocardiography and lung ultrasound are n

71 We hypothesize that a combination of transthoracic echocardiography and lung ultrasound is no

72 Transthoracic echocardiography and measurement of B-type

73 Transthoracic echocardiography and MRI are noninvasive i

74 ocardial depression measured by quantitative transthoracic echocardiography and peak inotrope require

75 venues and pathologies, ranging from surface transthoracic echocardiography and portable hand-held ec

76 mpared the results of pre- and postoperative transthoracic echocardiography and right heart catheteri

77 s is generally performed using 2-dimensional transthoracic echocardiography and TEE.

78 -matched control subjects underwent contrast transthoracic echocardiography and transcranial Doppler

79 hocardiography from the typical platforms of transthoracic echocardiography and transesophageal echoc

80 e study, women with HDP underwent peripartum transthoracic echocardiography and were evaluated for CH

81 ft ventricular mass index (LVMI) measured by transthoracic echocardiography and, in a subset, by card

82 We reviewed 405 ECGs, 315 transthoracic echocardiographies, and 441 implantable ca

83 , 16.7% of patients with E-BSI who underwent transthoracic echocardiography, and 35.5% of all patient

84 n, and late gadolinium enhancement imaging), transthoracic echocardiography, and applanation tonometr

85 uded pulmonary artery catheter measurements, transthoracic echocardiography, and blood gas analyses.

86 llowed by comprehensive clinical evaluation, transthoracic echocardiography, and clinical genetic tes

87 cipants underwent 12-lead electrocardiogram, transthoracic echocardiography, and exercise stress test

88 r electrocardiogram monitoring (24h-Holter), transthoracic echocardiography, and laboratory tests on

89 pected infective endocarditis should undergo transthoracic echocardiography, and most of these patien

90 m) study underwent psychometric assessments, transthoracic echocardiography, and platelet aggregation

91 sleep function by pulmonary function tests, transthoracic echocardiography, and polysomnography 3 mo

92 e sedimentation rate), an electrocardiogram, transthoracic echocardiography, and relevant clinical da

93 ssessment by standard biological parameters, transthoracic echocardiography, and right heart catheter

94 plethysmography, bioimpedance cardiography, transthoracic echocardiography, and sphygmomanometry, re

95 e imaging, contrast-enhanced two-dimensional transthoracic echocardiography, and three-dimensional tr

96 entricular ejection fraction (LVEF) >/=8% by transthoracic echocardiography, and/or ischemic ST-segme

97 Transthoracic echocardiography, aortic catheterization,

98 Mobile thrombi, not routinely recognized on transthoracic echocardiography, are frequently identifie

99 This emphasizes the importance of Doppler transthoracic echocardiography as a predictor of outcome

100 individuals with TS age 7 to 67 years using transthoracic echocardiography as our primary screening

101 e disease, or pericardial effusion; and used transthoracic echocardiography as the reference standard

102 n, ultrasound-guided regional anesthesia and transthoracic echocardiography as well as expand on a va

103 tive COVID-19 inpatients undergoing clinical transthoracic echocardiography at 3 New York City hospit

104 ts undergoing aortic valve repair, follow-up transthoracic echocardiography at a median of three mont

105 All patients who underwent outpatient transthoracic echocardiography at a university-based ter

106 AF were examined using serial 3-dimensional transthoracic echocardiography at admission, at 6 months

107 geometry and functioning were assessed using transthoracic echocardiography at baseline and follow-up

108 cognized as more sensitive and specific than transthoracic echocardiography at detecting vegetations

109 echocardiography was performed at inclusion (transthoracic echocardiography baseline).

110 l septal defect (SVD) is underdiagnosed with transthoracic echocardiography because of its posterior

111 Cardiac function was assessed by transthoracic echocardiography before fluid administrati

112 The remaining animals underwent transthoracic echocardiography before surgery and 7 days

113 All patients underwent transthoracic echocardiography before the operation.

114 Hemodynamic parameters, transthoracic echocardiography, biological data, and ele

115 Transthoracic echocardiography can visualize the left ve

116 Transthoracic echocardiography cannot reliably detect th

117 ic osteosarcoma was suggested by findings at transthoracic echocardiography, cardiac CT, and cardiac

118 rdial injury hospitalized for COVID-19 using transthoracic echocardiography, cardiac magnetic resonan

119 Five studies identified clinical or transthoracic echocardiography characteristics associate

120 Prior transthoracic echocardiography clearly defined the SVD i

121 Subjects underwent transthoracic echocardiography, CMR with routine cine ac

122 ry, exhaled nitric oxide, electrocardiogram, transthoracic echocardiography, computed tomography (CT)

123 dy testing group who underwent comprehensive transthoracic echocardiography confirming significant MR

124 Transthoracic echocardiography could not visualize the a

125 surveillance with imaging techniques such as transthoracic echocardiography, CT or MRI is necessary t

126 We designed and implemented a focused transthoracic echocardiography curriculum for critical c

127 A focused transthoracic echocardiography curriculum that includes

128 ssessed the association between clinical and transthoracic echocardiography data and a postpartum dia

129 Transthoracic echocardiography demonstrated severe right

130 unctional analysis of Cav-1/3 dKO hearts via transthoracic echocardiography demonstrates hypertrophy

131 d flow propagation velocity were assessed by transthoracic echocardiography during a prolonged intrac

132 Subcostal transthoracic echocardiography during catheter insertion

133 We collected a series of transthoracic echocardiography examinations performed be

134 y (76+/-5 years and 60% women) who underwent transthoracic echocardiography, excluding former drinker

135 In 4 studies, clinical or transthoracic echocardiography findings did not predict

136 ity was assessed as being moderate at 30-day transthoracic echocardiography follow-up in all patients

137 ardiac triad testing (12-lead ECG, troponin, transthoracic echocardiography) followed by cardiac magn

138 Cardiac performance was assessed by transthoracic echocardiography following experimental ba

139 s to their presence, that TEE is superior to transthoracic echocardiography for detecting left atrial

140 ese studies provide the first application of transthoracic echocardiography for morphological/functio

141 All subjects underwent transthoracic echocardiography for significant valvular

142 egurgitant jet velocity >/=3.2 m/s (3.6%) on transthoracic echocardiography further underwent right h

143 ulmonary artery pressure (sPAP) estimated in transthoracic echocardiography: group I, sPAP <40 mm Hg

144 ng an HR-guided (HR group) versus a standard transthoracic echocardiography-guided (control group) ma

145 Two-dimensional transthoracic echocardiography has been used to study pa

146 essential for triage; however, comprehensive transthoracic echocardiography has limited availability.

147 ated whether two-dimensional high-resolution transthoracic echocardiography (HR-2DTTE) can detect cha

148 may provide a non-invasive alternative when transthoracic echocardiography image quality is insuffic

149 cine fellows to obtain and interpret focused transthoracic echocardiography images from critically il

150 w's ability to interpret prerecorded focused transthoracic echocardiography images.

151 Transthoracic echocardiography imaging was performed to

152 y was to determine whether contrast-enhanced transthoracic echocardiography improves the evaluation o

153 We performed supine and upright transthoracic echocardiography in 118 patients with unex

154 RV remodeling was characterized by transthoracic echocardiography in 1292 patients with sig

155 We performed resting transthoracic echocardiography in 855 subjects with coro

156 ith altered cardiac function, as assessed by transthoracic echocardiography in conscious mice.

157 icular function as measured by 2-dimensional transthoracic echocardiography in contrast to 67.1% in c

158 To date, no studies have defined the role of transthoracic echocardiography in evaluating long-term m

159 in 26 of 86 patients (30%) but were seen on transthoracic echocardiography in only 1 of the 26 patie

160 Our data advocate a role for transthoracic echocardiography in risk stratification in

161 rated alternative to invasive techniques and transthoracic echocardiography in the assessment of aort

162 and in 50 768 individuals who had undergone transthoracic echocardiography in the Community Care Coh

163 Mean pulmonary artery pressure, estimated by transthoracic echocardiography, increased after transfus

164 Transthoracic echocardiography indicated reverse LV remo

165 ventilated critically ill patients, Doppler transthoracic echocardiography indices are highly specif

166 accuracy of agitated saline bubble-enhanced transthoracic echocardiography is equivalent to the ches

167 The frequency of valvular monitoring by transthoracic echocardiography is guided by the disease

168 Although transthoracic echocardiography is often sufficient for t

169 After TAVI, transthoracic echocardiography is performed to assess tr

170 Transthoracic echocardiography is the principal method c

171 a low LVSWI, as measured noninvasively using transthoracic echocardiography, is associated with highe

172 Using transthoracic echocardiography, left ventricular fractio

173 Transthoracic echocardiography (M-mode and Doppler) offe

174 Transthoracic echocardiography of LV function was perfor

175 rior vena cava diameter (IVC) measured using transthoracic echocardiography, of the maximal Doppler v

176 However, transthoracic echocardiography often produces poor-quali

177 ifficult to diagnose at plain radiography or transthoracic echocardiography, often leading to further

178 Patients underwent adenosine transthoracic echocardiography on two occasions--immedia

179 nesthesia, inotrope and vasopressor support, transthoracic echocardiography, optimization of delivery

180 erload or suspected intracardiac shunting by transthoracic echocardiography or intraoperatively.

181 12 months of follow-up assessed both through transthoracic echocardiography (P=0.0167 versus baseline

182 BMI measured on admission, and 2-dimensional transthoracic echocardiography performed within 48 hours

183 with symptomatic, severe aortic stenosis and transthoracic echocardiography pre- and post-transcathet

184 Transthoracic echocardiography provides a practical meth

185 determined whether Doppler and 2-dimensional transthoracic echocardiography reliably assess hemodynam

186 Transthoracic echocardiography remains a primary tool fo

187 Transthoracic echocardiography revealed a mean+/-SD ejec

188 Transthoracic echocardiography revealed a normal tricusp

189 Transthoracic echocardiography revealed an irregular rig

190 Transthoracic echocardiography revealed MR only in the h

191 cause of an out-of-hospital cardiac arrest, transthoracic echocardiography should be performed to sc

192 Transthoracic echocardiography showed a significantly in

193 At 30 days, transthoracic echocardiography showed mild (1+) central

194 ages from critically ill patients and a from transthoracic echocardiography simulator.

195 Transthoracic echocardiography, stress echocardiography,

196 ntifying clinically significant MR from full transthoracic echocardiography studies demonstrated exce

197 Transthoracic echocardiography, TEE and TCD have been us

198 Using transthoracic echocardiography, there may be technical i

199 was to prospectively evaluate the ability of transthoracic echocardiography to assess pulmonary arter

200 All subjects underwent transthoracic echocardiography to determine Doppler vari

201 Development of hypertrophy was followed by transthoracic echocardiography to measure left ventricul

202 tion (standard 12-lead electrocardiogram and transthoracic echocardiography) to the cardiology depart

203 Agitated-saline bubble studies with transthoracic echocardiography/transcranial Doppler +/-

204 sts of nine diagnostic strategies, including transthoracic echocardiography, transesophageal echocard

205 Multimodality imaging, which includes transthoracic echocardiography, transesophageal echocard

206 Options for the diagnosis of PFO include transthoracic echocardiography, transesophageal echocard

207 ardiac imaging are often required, including transthoracic echocardiography, transesophageal echocard

208 ents with S aureus bacteremia should undergo transthoracic echocardiography; transesophageal echocard

209 apparent improvements in appropriateness for transthoracic echocardiography (TTE) (80% [95% confidenc

210 t right heart catheterization (RHC), CMR and transthoracic echocardiography (TTE) (validation cohort

211 ention of endocarditis included a systematic transthoracic echocardiography (TTE) and a 12-month cour

212 Both transthoracic echocardiography (TTE) and cardiac magneti

213 Systematic contrast transthoracic echocardiography (TTE) and cerebral magnet

214 Artificial intelligence (AI)-enabled transthoracic echocardiography (TTE) and electrocardiogr

215 left ventricular mass (LVM) regression with transthoracic echocardiography (TTE) and magnetic resona

216 ascular system coupled with patient-specific transthoracic echocardiography (TTE) and right heart cat

217 It is unclear whether Doppler transthoracic echocardiography (TTE) and transesophageal

218 f three strategies: 1) conventional therapy--transthoracic echocardiography (TTE) and warfarin therap

219 umenting its accuracy compared with standard transthoracic echocardiography (TTE) are not available.

220 rred for pharmacological stress testing with transthoracic echocardiography (TTE) are unable to under

221 The value of performing transthoracic echocardiography (TTE) as part of the clin

222 lobal LV function and RWM were compared with transthoracic echocardiography (TTE) by using multidetec

223 Focused transthoracic echocardiography (TTE) during cardiac arre

224 ct the presence of LAT based on clinical and transthoracic echocardiography (TTE) features.

225 ial blood flow (MBF) quantification, resting transthoracic echocardiography (TTE) for assessment of m

226 d meta-analysis evaluated the performance of transthoracic echocardiography (TTE) for diagnosis of pr

227 ence range for PASP as determined by Doppler transthoracic echocardiography (TTE) from a clinical ech

228 teria (AUC) for initial pediatric outpatient transthoracic echocardiography (TTE) have not yet been e

229 In 35 cases (72%), transthoracic echocardiography (TTE) identified a valvul

230 is study were to determine LVH prevalence by transthoracic echocardiography (TTE) in a high-risk grou

231 fit of cardiac magnetic resonance (CMR) over transthoracic echocardiography (TTE) in ischemic cardiom

232 Methods: We performed transthoracic echocardiography (TTE) in patients with st

233 The diagnostic value of transthoracic echocardiography (TTE) in the detection of

234 olds of AVCa measured on contrast CT against transthoracic echocardiography (TTE) measures of AS.

235 a from right heart catheterization (RHC) and transthoracic echocardiography (TTE) of heart failure (H

236 ional initiatives have been shown to improve transthoracic echocardiography (TTE) ordering practices

237 dysfunction (DD) using CMR by comparing with transthoracic echocardiography (TTE) performed on the sa

238 They received transthoracic echocardiography (TTE) to detect or exclud

239 vascular magnetic resonance (MR) imaging and transthoracic echocardiography (TTE) were performed in 1

240 before CABG, and 68 (50%) had postoperative transthoracic echocardiography (TTE) within 6 weeks of s

241 that for the diagnosis of endocarditis, (1) transthoracic echocardiography (TTE) would be most valua

242 METHODS AND After baseline transthoracic echocardiography (TTE), adult ICR mice wer

243 on, (b) feasibility and usefulness of repeat transthoracic echocardiography (TTE), and (c) whether th

244 E), intracardiac echocardiography (ICE), and transthoracic echocardiography (TTE), selected at the op

245 tomic and functional sizing of a PFO include transthoracic echocardiography (TTE), transesophageal ec

246 g), and nine were diagnosed prospectively by transthoracic echocardiography (TTE).

247 e potential to improve the interpretation of transthoracic echocardiography (TTE).

248 valvular lesions in 802 patients undergoing transthoracic echocardiography using logistic regression

249 ch patient underwent electrocardiography and transthoracic echocardiography.Valvular disease was comm

250 ble to rapidly obtain five essential focused transthoracic echocardiography views: parasternal long a

251 nce between goal-directed echocardiogram and transthoracic echocardiography was 21 hours 18 minutes.

252 A protocol using transthoracic echocardiography was designed to diagnose

253 Transthoracic echocardiography was done 6 months after t

254 l examination and history were obtained, and transthoracic echocardiography was performed according t

255 Transthoracic echocardiography was performed at baseline

256 Transthoracic echocardiography was performed at baseline

257 Transthoracic echocardiography was performed at inclusio

258 Two-dimensional transthoracic echocardiography was performed in 1818 par

259 Postprocedural transthoracic echocardiography was performed in 2769 (92

260 Transthoracic echocardiography was performed in 38 patie

261 Gold standard transthoracic echocardiography was performed on schedule

262 Transthoracic echocardiography was performed simultaneou

263 Clinical events were recorded and a transthoracic echocardiography was performed to evaluate

264 Transthoracic echocardiography was used in a protocol de

265 Standard transthoracic echocardiography was used to obtain apical

266 t 30 days and 6 months, assessed by contrast transthoracic echocardiography, was 48 (92%) of 52 and 5

267 Using transthoracic echocardiography we measured f(H), and str

268 t disease who underwent clinically indicated transthoracic echocardiography were enrolled in a single

269 Cardiac auscultation and transthoracic echocardiography were performed by 2 indep

270 microspheres) and regional wall thickening (transthoracic echocardiography) were measured in pigs st

271 Transthoracic echocardiography, which combines structura

272 assessment of MR has been with 2-dimensional transthoracic echocardiography, which is often used as a

273 llowed by an agitated saline bubble-enhanced transthoracic echocardiography, which was used to locali

274 Diagnostic modalities include transthoracic echocardiography with or without ultrasoun

275 PFO presence was assessed by transthoracic echocardiography with saline contrast inje

276 Residual shunt was evaluated by transthoracic echocardiography with saline contrast.

277 The advancement of transthoracic echocardiography with tissue Doppler imagi

278 easure of heart failure by a novel method of transthoracic echocardiography (with intravascular ultra

279 e identified patients with LVSWI measured by transthoracic echocardiography within 1 day of CICU admi

280 or 21-mm St Jude Medical prostheses and had transthoracic echocardiography within 1 year after AVR.

281 atheterization to evaluate AS also underwent transthoracic echocardiography within 24 hours.

282 grams, 110 with complete cardiology-reviewed transthoracic echocardiography within 48 hours for compa

283 jection fraction and GLVMWE were measured by transthoracic echocardiography within 48 hours of admiss

284 Reduced GLVMWE (<86%) measured by transthoracic echocardiography within 48 hours of admiss

285 tral annular velocities (e') with the use of transthoracic echocardiography within 48 hours of cardia

286 Transthoracic echocardiography within 60 days after birt

287 ional (2D) parasternal long axis videos from transthoracic echocardiography without Doppler imaging t

288 f a significant shunt cannot be ruled out by transthoracic echocardiography without the use of bubble

289 ening first-degree relatives for AAOCA using transthoracic echocardiography would be the prudent appr